Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis.

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation Pub Date : 2025-05-14 DOI:10.1016/j.hlc.2025.01.011

Rahil Ajmera, Hassan Karim, P Gerry Fegan, Girish Dwivedi, Nick S R Lan

引用次数: 0

查看原文本刊更多论文

急性心肌梗死、超重或肥胖无糖尿病患者服用2.4 mg西马鲁肽的资格：一项现实世界分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart, Lung and Circulation CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

4.50

自引率

3.80%

发文量

912

审稿时长

11.9 weeks

期刊介绍： Heart, Lung and Circulation publishes articles integrating clinical and research activities in the fields of basic cardiovascular science, clinical cardiology and cardiac surgery, with a focus on emerging issues in cardiovascular disease. The journal promotes multidisciplinary dialogue between cardiologists, cardiothoracic surgeons, cardio-pulmonary physicians and cardiovascular scientists.